Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:47:35.994Z.
Calculation as of: 2026-10-06T15:47:35.994Z.
Quote observation: 2026-10-06T15:43:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
EARNINGS YIELD
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$217.70M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.04M
Earnings Yield
6.90%
TTM Avg
4.72%
3Y Avg
3.13%
5Y Avg
3.13%
Market Cap
$216.19M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$226.43M
Earnings Yield
N/A
TTM Avg
9.26%
3Y Avg
9.26%
5Y Avg
9.26%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $217.70M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $215.04M | 6.90% | 4.72% | 3.13% | 3.13% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $215.13M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $215.58M | 16.46% | 15.50% | 9.57% | 9.57% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.19M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $219.27M | N/A | 3.98% | 3.98% | 3.98% |
| Pro-Dex, Inc. (PDEX)vs › | $207.89M | 6.33% | 7.28% | 6.45% | 6.38% |
| Profound Medical Corp. (PROF)vs › | $228.93M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $226.43M | N/A | 9.26% | 9.26% | 9.26% |
| Electra Therapeutics Inc. (ETRA)vs › | $202.47M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute